We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Stopping Excessive Bone Growth Following Trauma or Surgery

By HospiMedica International staff writers
Posted on 07 Oct 2009
A new study describes a way to prevent heterotopic ossificiation (HO)--which affects up to 70% of soldiers who are severely wounded during combat--by shutting the process off in its early stages. More...


Researchers at Thomas Jefferson University (Jefferson, Philadelphia, PA, USA) examined the synthetic retinoid NRX195183, a potent and highly selective retinoic acid receptor alpha (RARalpha) agonist, to see if it inhibited chondrogenesis in mouse limb-micromass cultures. The researchers hoped that it would also inhibit HO, since chondrogenesis requires a decrease of nuclear RARalpha action. To do so, the researchers established a mouse HO model consisting of subcutaneous implantation of Matrigel mixed with rhBMP-2. Control mice that received daily oral doses of peanut oil or retinol (a natural nonactive retinoid precursor) developed large HO-like masses by days 9-12 that displayed abundant cartilage, endochondral bone, vessels, and marrow. In contrast, formation of HO-like masses was markedly reduced in the study companion mice that received daily oral doses of the alpha-agonist. The study was published in the September 2009 issue of the Journal of Orthopedic Research.

"We are able to largely prevent formation and progression of HO lesions,” said primary investigator Maurizio Pacifici, Ph.D, director of orthopedic research at Jefferson. "We presented our initial results at a recent U.S. Army Extremity War Injuries Symposium in Washington D.C., and they were very well-received and have elicited great hope on the part of military physicians to finally have a way to stop HO in troops wounded in war zones.”

Heterotopic ossification (HO) consists of formation of ectopic cartilage followed by endochondral bone and is triggered by major surgeries, large wounds, and other conditions. The excessive bone forms within muscles and other tissues, causing severe pain, reduced mobility, and even local paralysis if untreated. Current therapies, including low-dose irradiation, are not always effective and do not target the skeletogenic process directly. Hopefully, if clinical trials prove successful, the proposed treatment could be used as a cure for not only HO but for other HO-related diseases including Fibrodysplasia Ossificans Progressive (FOP), an inheritable and severe form of HO.

Related Links:
Thomas Jefferson University




Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.